164 related articles for article (PubMed ID: 31906724)
41. Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer.
Bartsch R; Rottenfusser A; Wenzel C; Dieckmann K; Pluschnig U; Altorjai G; Rudas M; Mader RM; Poetter R; Zielinski CC; Steger GG
J Neurooncol; 2007 Dec; 85(3):311-7. PubMed ID: 17557136
[TBL] [Abstract][Full Text] [Related]
42. Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial.
Coudert B; Pierga JY; Mouret-Reynier MA; Kerrou K; Ferrero JM; Petit T; Kerbrat P; Dupré PF; Bachelot T; Gabelle P; Giard S; Coeffic D; Bougnoux P; Prevost JB; Paintaud G; Thibault G; Hernandez J; Coudert M; Arnould L; Berriolo-Riedinger A
Lancet Oncol; 2014 Dec; 15(13):1493-1502. PubMed ID: 25456368
[TBL] [Abstract][Full Text] [Related]
43. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial.
van Ramshorst MS; van der Voort A; van Werkhoven ED; Mandjes IA; Kemper I; Dezentjé VO; Oving IM; Honkoop AH; Tick LW; van de Wouw AJ; Mandigers CM; van Warmerdam LJ; Wesseling J; Vrancken Peeters MT; Linn SC; Sonke GS;
Lancet Oncol; 2018 Dec; 19(12):1630-1640. PubMed ID: 30413379
[TBL] [Abstract][Full Text] [Related]
44. Long-term survival with eribulin monotherapy after whole brain radiation therapy in a patient with brain metastasis from breast cancer.
Jung SU; Jeon CW; Choi JH
Asian J Surg; 2020 Oct; 43(10):1008-1009. PubMed ID: 32631621
[No Abstract] [Full Text] [Related]
45. Trastuzumab-based Retreatment after Lapatinib in Heavily Pretreated HER2 Positive Metastatic Breast Cancer: an Anatolian Society of Medical Oncology Study.
Uncu D; Bayoglu IV; Arslan UY; Kucukoner M; Artac M; Koca D; Oguz A; Demirci U; Arpaci E; Dogan M; Kucukzeybek Y; Turker I; Isikdogan A; Guler T; Zengin N
Asian Pac J Cancer Prev; 2015; 16(9):4127-31. PubMed ID: 25987098
[TBL] [Abstract][Full Text] [Related]
46. [Clinical value of trastuzumab in the treatment of lapatinib-resistant HER2-positive metastatic breast cancer].
Ma F; Xu BH; Li HH; Li Q; Zhang P; Yuan P; Wang JY; Fan Y; Li Q
Zhonghua Zhong Liu Za Zhi; 2013 Jul; 35(7):521-4. PubMed ID: 24257305
[TBL] [Abstract][Full Text] [Related]
47. Lapatinib-plus-pegylated liposomal doxorubicin in advanced HER2-positive breast cancer following trastuzumab: a phase II trial.
Pircher M; Mlineritsch B; Fridrik MA; Dittrich C; Lang A; Petru E; Weltermann A; Thaler J; Hufnagl C; Gampenrieder SP; Rinnerthaler G; Ressler S; Ulmer H; Greil R
Anticancer Res; 2015 Jan; 35(1):517-21. PubMed ID: 25550597
[TBL] [Abstract][Full Text] [Related]
48. Pertuzumab in HER2-positive early breast cancer: current use and perspectives.
Eiger D; Pondé NF; de Azambuja E
Future Oncol; 2019 Jun; 15(16):1823-1843. PubMed ID: 30938542
[TBL] [Abstract][Full Text] [Related]
49. Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study.
Murthy R; Borges VF; Conlin A; Chaves J; Chamberlain M; Gray T; Vo A; Hamilton E
Lancet Oncol; 2018 Jul; 19(7):880-888. PubMed ID: 29804905
[TBL] [Abstract][Full Text] [Related]
50. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
Gianni L; Romieu GH; Lichinitser M; Serrano SV; Mansutti M; Pivot X; Mariani P; Andre F; Chan A; Lipatov O; Chan S; Wardley A; Greil R; Moore N; Prot S; Pallaud C; Semiglazov V
J Clin Oncol; 2013 May; 31(14):1719-25. PubMed ID: 23569311
[TBL] [Abstract][Full Text] [Related]
51. [Combination therapy herceptin+xeloda].
Schaller G
Onkologie; 2002 Dec; 25 Suppl 5():17-8; discussion 19. PubMed ID: 23573615
[No Abstract] [Full Text] [Related]
52. Factors influencing the time to development of brain metastases in breast cancer.
Fromm S; Bartsch R; Rudas M; de Vries A; Wenzel C; Steger GG; Zielinski CC; Poetter R; Dieckmann K
Breast; 2008 Oct; 17(5):512-6. PubMed ID: 18486473
[TBL] [Abstract][Full Text] [Related]
53. [Chemotherapy in the treatment of brain metastases of breast cancers].
Couteau C; Chevallier B; Bastit P
Bull Cancer; 1994 Mar; 81(3):226-9. PubMed ID: 7894132
[TBL] [Abstract][Full Text] [Related]
54. Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy.
Burstein HJ; Lieberman G; Slamon DJ; Winer EP; Klein P
Ann Oncol; 2005 Nov; 16(11):1772-7. PubMed ID: 16150805
[TBL] [Abstract][Full Text] [Related]
55. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
[TBL] [Abstract][Full Text] [Related]
56. Biological subtypes and survival outcomes in breast cancer patients with brain metastases (study of the Anatolian Society of Medical Oncology).
Kaplan MA; Isikdogan A; Koca D; Kucukoner M; Gumusay O; Yildiz R; Dayan A; Demir L; Geredeli C; Kocer M; Arslan UY; Inal A; Unal OU; Mert AG; Bilici M; Ozkan M; Elkiran ET; Yaman S; Durnalı AG; Suner A; Alici S; Tarhan MO; Boruban C; Urakci Z; Buyukberber S
Oncology; 2012; 83(3):141-50. PubMed ID: 22814315
[TBL] [Abstract][Full Text] [Related]
57. A Multidisciplinary Breast Cancer Brain Metastases Clinic: The University of North Carolina Experience.
McKee MJ; Keith K; Deal AM; Garrett AL; Wheless AA; Green RL; Benbow JM; Dees EC; Carey LA; Ewend MG; Anders CK; Zagar TM
Oncologist; 2016 Jan; 21(1):16-20. PubMed ID: 26659221
[TBL] [Abstract][Full Text] [Related]
58. Two cases with long-term disease-free survival after resection and radiotherapy for solitary brain metastasis from breast cancer with extensive nodal metastases.
Saisho S; Takashima S; Ohsumi S; Saeki H; Aogi K; Saeki T; Mandai K; Iwata S; Takeda T
Breast Cancer; 2005; 12(3):221-5. PubMed ID: 16110293
[TBL] [Abstract][Full Text] [Related]
59. Challenges in the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer with brain metastases.
Liu MC; Cortés J; O'Shaughnessy J
Cancer Metastasis Rev; 2016 Jun; 35(2):323-32. PubMed ID: 27023712
[TBL] [Abstract][Full Text] [Related]
60. Breast cancer subtypes and response to systemic treatment after whole-brain radiotherapy in patients with brain metastases.
Niwińska A; Murawska M; Pogoda K
Cancer; 2010 Sep; 116(18):4238-47. PubMed ID: 20549816
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
